Physician profile
Chastity R Frederick
NPI 1780244970
$1,436.75
in general payments reported to CMS, 2019-2025
27 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.15 · 2023: $175 · 2024: $579 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $269.96 | 2024-2025 | Airsupra, Farxiga, Lynparza |
| Novartis Pharmaceuticals Corporation | $142.30 | 2023-2025 | |
| Novo Nordisk INC | $129.61 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $86.68 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.28 | 2025 | Fruzaqla, Iclusig |
| Otsuka America Pharmaceutical, INC. | $77.86 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $69.88 | 2024 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $69.56 | 2025 | Datroway, Enhertu |
| Phathom Pharmaceuticals, INC. | $64.57 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $54.88 | 2025 | Keytruda, Lynparza |
| Ironshore Pharmaceuticals INC. | $48.20 | 2023 | Jornay Pm |
| Adaptive Biotechnologies Corporation | $32.78 | 2025 | Clonoseq |
| Janssen Biotech, INC. | $28.29 | 2025 | Erleada |
| Incyte Corporation | $27.88 | 2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $26.46 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.47 | 2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $22.75 | 2025 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $21.85 | 2025 | Revuforj |
| Lundbeck LLC | $20.56 | 2024 | Rexulti |
| Baxter Healthcare | $20.15 | 2022 | |
| Recordati_rare_diseases_inc. | $18.30 | 2025 | Sylvant |
| Corium, LLC | $17.30 | 2024 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $16.75 | 2025 | Libtayo |
| Lilly USA, LLC | $16.28 | 2025 | |
| Legend Biotech USA INC. | $16.16 | 2025 | Carvykti |
| Beone Medicines USA, INC. | $15.76 | 2025 | Brukinsa |
| Dynavax Technologies Corporation | $15.23 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chastity Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.